FL-WAX
22.11.2021 14:51:07 CET | Business Wire | Press release
Metasaurs , one of the fastest-growing NFT communities in the world, and WAX ($3.5B market cap), the most utilized blockchain in the world for games, processing three-quarters of all game-related transactions daily, announced a ground-breaking partnership to bring new world-class P2E (play-to-earn) games to the WAX ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211122006228/en/
The creators of Metasaurs and founders of WAX will be co-founding a new NFT gaming studio, MetaGames to develop new game projects including the official Metasaurs Game and the launch of the RAWR token to be released in Q1 2022.
Since its inception in 2017, WAX has been coined “The King of NFTs,” but it’s so much more. WAX’s vIRL® technology is leading the future of digital commerce and it is the #1 blockchain by transaction volume in the world. It currently has more than 8M monthly users and is growing 400k+ users per month.
The WAX gaming-optimized blockchain processes 15 million transactions per day and is the #2 layer-1 blockchain behind only Ethereum in daily and 30 day NFT sales volume. Alien Worlds, one of the most popular games in the world, is built on the WAX blockchain, and independently boasts a $2.3B market cap for its own in-game economy.
"The foundation of WAX was built on gaming,” said William E. Quigley, co-founder of WAX, “and the official Metasaurs Game is the perfect use case for a play-to-earn gaming franchise created on WAX, taking advantage of our high volume transaction capacity, unique fee structure of no minting and gifting transaction fees, and energy efficient and low carbon footprint.”
Metasaurs are Dinosaur-Bored Ape hybrids of the popular Bored Ape Yacht Club NFT. The extended storyline, based on Dr. DMT, creating the Metasaurs, unlocks endless creative potential with regard to future games, avatars, and other multi-media on the WAX platform and across the emerging metaverse.
"It is our mission to create fun games which will share their economies with the lifeblood of the community—the players—rather than siphoning all value only to the publishers,” said Merlin Kauffman, creator of Metasaurs. ”Blockchain technology is best suited for this use-case, and we are excited to partner with WAX to create differentiated gaming experiences for the mass market."
“Merlin is a grassroots thought-leader in the NFT space,” said Quigley. “His track record building one of the most passionate fastest-growing NFT communities combined with our deep knowledge of NFT gaming economies put us in a privileged position to co-create the official Metasaurs Game. Our gaming studio, MetaGames, has all the right ingredients to create a series of successful play-to-earn gaming franchises.”
Quigley continued, “As we spend an increasing amount of time virtually than ever before, NFTs pave a way for users to have a stake in these new applications and digital worlds. WAX is at the forefront of this gaming evolution in the way we live online, building tools in a way that benefits everyone involved.”
About Metasaurs
The genesis Metasaurs collection is 9,999 NFTs created by Dr. DMT in The Lab from 300+ hand-drawn traits, each Metasaur consists of between 4-7 combined traits, of various rarities. Dr. DMT is authentic BAYC Ape #4588, and he is constantly developing new formulas to expand the Metasaurs experiment. The possibilities are endless, like the infinite lifespans of these Metasaurs on the blockchain .
About WAX - The King of NFTs
The Worldwide Asset eXchange ™ (WAX), aka the King of NFTs, is the world’s #1 blockchain, as measured by number of users and transactions, according to Dappradar.com. WAX’s mission is to bring NFTs to the mass market in the safest, most secure, environmentally friendly, and easy-to-use marketplace in the world. WAX is also the leading entertainment NFT network — in 2018, WAX introduced vIRLs® , giving consumer product companies the ability to directly link NFTs to physical consumer products.
About MetaGames Studio
Creators of world-class games, we are building the future of play-to-earn gaming experiences on the WAX blockchain. Co-founded by William Quigley, Merlin Kauffman, and Ben Bindell in 202, with initial studio development of the official Metasaurs Game and RAWR token to be released in Q1 2022. MetaGames ’ mission is to build branded social gaming communities that share their economies with the players, rather than siphoning all of the value only to the game publishers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom